28 Sep 2015 13:17
For Immediate Release 28 September 2015
Sphere Medical Holding plc
("Sphere Medical" or the "Company")
Director Dealing
Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that it was informed on 28 September 2015 that on 28 September 2015 Richard Wright, Chief Financial Officer of the Company, purchased 75,382 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 13.25 pence per share. Following this transaction, Mr Wright's holding in the Company is 75,382 Ordinary Shares, representing 0.05 per cent. of the Company's issued share capital.
- Ends -
For further information, please contact:
Sphere Medical Holding plc | Tel: +44 (0)1223 875 222 | |
Dr Wolfgang Rencken, Chief Executive Officer | ||
Richard Wright, Chief Financial Officer | ||
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 | |
James Steel | ||
Oliver Jackson | ||
Jock Maxwell Macdonald | ||
finnCap | Tel: +44 (0) 20 7220 0500 | |
Geoff Nash / Simon Hicks | ||
Stephen Norcross | ||
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 | |
Mary-Jane Elliott | spheremedical@consilium-comms.com | |
Chris Gardner Ivar Milligan | ||
Hendrik Thys | ||
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.
Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.
The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.
Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.
For further information, please visit www.spheremedical.com
Sphere Medical Holding (SPHR)